On Friday, the Food and Drug Administration approved the updated Covid shot from Novavax for emergency use.
The modified vaccine, which targets the JN.1 strain of the virus, is approved for use in people 12 years of age and older. Late afternoon trading saw a 9% increase in the company’s shares.
The FDA’s Centre for Biologics Evaluation and Research director, Peter Marks, stated that the authorisation granted today offers a second option for the Covid-19 vaccine.
The company responded via email, saying that doses are expected to be available as early as the end of next week.
Updated Covid vaccines targeting the KP.2 variant were approved by the health regulator earlier this month. Pfizer and Moderna made the vaccines.
In the US earlier this year, JN.1 was the most common strain. According to data from the Centres for Disease Control and Prevention, it was estimated to have contributed 0.2% of cases during a two-week period ending on August 31, although it is no longer as common.
Also Read:
Factors to Watch Next Week: FIIs, Rate Cut, and Economic Data
